Clinical Trials Logo

Barrett's Esophagus clinical trials

View clinical trials related to Barrett's Esophagus.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT02427269 Enrolling by invitation - Esophageal Cancer Clinical Trials

University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository

BEECAB
Start date: April 28, 2015
Phase:
Study type: Observational

Aim 1: To develop a prospective tissue and blood biorepository from patients with a history of Barrett's Esophagus (BE) or esophageal cancer (ECA) presenting to UNC hospitals for routine care upper endoscopy for their condition. Aim 2: To collect clinical data from patients with a history of Barrett's Esophagus (BE) or esophageal cancer (ECA) that includes demographic data, endoscopic procedure data, and pathology data. Aim 3: To integrate Aim 1 and 2 in a manner that will provide an efficient bi-directional flow of clinical information and specimens between laboratory and clinical scientists in order to foster innovative translational research. Aim 4: To create a biorepository for future Institutional Review Board (IRB) approved studies that have tissue and/or blood specimen component.

NCT ID: NCT02149914 Enrolling by invitation - Barrett's Esophagus Clinical Trials

The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients

Start date: May 2014
Phase: N/A
Study type: Interventional

Gastroesophageal reflux disease(GERD) mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter. Proton pump inhibitors (PPI) can effectively block gastric acid secretion but the drug reactions and the degree of improvement in symptoms are sometimes unpredictable. The aim of this study is to investigate the association between the clinical efficacy of PPI in patients with GERD and the personal physical status by Ryodoraku and ANSWatch.

NCT ID: NCT01905202 Enrolling by invitation - Barrett's Esophagus Clinical Trials

The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus

Start date: April 2013
Phase: Phase 1
Study type: Interventional

Secretrol administered over a 6 month period to patients with Barrett's Esophagus will be safe and well tolerated. Further, pH control will be evaluated in the distal esophageal mucosa and just below the squamocolumnar junction.

NCT ID: NCT00587314 Enrolling by invitation - Barrett's Esophagus Clinical Trials

The Effect of Ablation Therapy on Barrett's Esophagus

ablation IN BE
Start date: January 2004
Phase:
Study type: Observational

To assess the effect of ablative therapy (Photodynamic Therapy or Radiofrequency ablation ) on Barrett's Esophagus